Pharmaceutical Biotechnology

1: Molecular Biotechnology: From DNA Sequence to Therapeutic Protein.- 2: Biophysical and Biochemical Analysis of Recombinant Proteins.- 3: Production and Purification of Recombinant Proteins.- 4: Formulation of Biotech Products, Including Biopharmaceutical Considerations.- 5: Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics.- 6: Immunogenicity of Therapeutic Proteins.- 7: Monoclonal Antibodies: From Structure to Therapeutic Application.- 8: Genomics, Other "Omic" Technologies, Personalized Medicine, and Additional Biotechnology-Related Techniques.- 9: Dispensing Biotechnology Products: Handling, Professional Education, and Product Information.- 10: Economic Considerations in Medical Biotechnology.- 11: Regulatory Framework for Biosimilars.- 12: Insulin.- 13: Follicle-Stimulating Hormone.- 14: Human Growth Hormone.- 15: Recombinant Coagulation Factors and Thrombolytic Agents.- 16: Recombinant Human Deoxyribonuclease I.- 17: Monoclonal Antibodies in Cancer.- 18: Hematopoietic Growth Factors: Focus on Erythropoiesis-Stimulating Agents.- 19: Monoclonal Antibodies in Solid Organ Transplantation.- 20: Monoclonal Antibodies and Antibody-Based Biotherapeutics in Inflammatory Diseases.- 21: Interferons and Interleukins.- 22: Vaccines.-  23: Oligonucleotides.- 24: Gene Therapy.- 25: Stem Cell Technology

DAAN J.A. CROMMELIN is Professor at the Department of Pharmaceutics at Utrecht University. Until December 2011 he was scientific director of the Dutch Top Institute Pharma in Leiden. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Dr. Crommelin is co-founder of OctoPlus, a Leiden based company specialized in the development of pharmaceutical product formulations and advanced drug delivery systems. He published over 335 articles and has held leadership positions at the International Pharmaceutical Federation (FIP) and the European Federation for Pharmaceutical Sciences (EUFEPS).